Skip to Content
Søg Menu
8.-16. juni 2023

Følg med når vi dækker EHA 2023 l European Hematology Association’s Annual Congress

Nyheder fra EHA 2022

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

  • / Daniel Kristensen

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Hæmatologi / Eunice Wang

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Hæmatologi / Jad Othman

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

/ Hæmatologi / Ali Bazarbachi

AML-highlights fra ASH22 – i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen

Evidence to use MRD after induction therapy of AML

/ Hæmatologi / Jacqueline Cloos
Se oversigt

CLL

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Onkologi / Christine Ryan

CLL – The impact of using ibrutinib as front-line treatment

/ Hæmatologi / Ryan Jacobs

CLL – Update fra ASH 2022

/ Hæmatologi / Carsten Utoft Niemann

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Hæmatologi / Jennifer R. Brown

Several interesting combinations of therapies with Calquence for patients with CLL

/ Hæmatologi / Matthew S. Davids
Se oversigt

Lymfom

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Hæmatologi / Roch Houot

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Hæmatologi / Frederick L. Locke

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

/ Hæmatologi / Johannes Schetelig

The impact of the molecular profile and treatment of older and fragile patients with relapsed/refractory FLT3-mutated AML

/ Hæmatologi / Marina Konopleva

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Hæmatologi / Martin Hutchings
Se oversigt

Myelomatose

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Hæmatologi / Matilde Slot

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Hæmatologi / Paul G. Richardson

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Hæmatologi / Sagar Lonial

Genomic aberrations as prognostic factors for time-limited Venclyxto, Venetoclax-based combinations

/ Hæmatologi / Eugen Taucsh

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Hæmatologi / Agoston Gyula Szabo
Se oversigt

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Paolo Strati

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Paolo Strati
EHA22Lymfom Play the Video
Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ Kirsten Grønbæk
EHA22 Play the Video

Mere fra EHA 2021

Significant improvements in OS and RFS for older patients with AML

/ Farhad Ravandi
EHA21AML Play the Video

Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma

/ Sagar Lonial
EHA21Myelomatose Play the Video

Highlights fra EHA 2021 (2:2)

/ Fredrik Schjesvold / Agoston Gyula Szabo
EHA21Myelomatose Play the Audio

Highlights fra EHA 2021 (1:2)

/ Fredrik Schjesvold / Agoston Gyula Szabo
EHA21Myelomatose Play the Audio

EHA-ESMO Clinical Practice Guidelines for Multiple Myeloma

/ Fredrik Schjesvold
EHA21Myelomatose Play the Video

Potential to become the best treatment for multiple myeloma in history

/ Thierry Facon
EHA21Myelomatose Play the Video
Læs mere

New bispecific antibody with promising efficacy and safety profil for patients with relapsed/refractory Multiple Myeloma

/ Amrita Y. Krishnan
EHA21Myelomatose Play the Video

Azacitidin tolereredes generelt godt af ældre patienter med AML

/ BestPractice Nordic
AlderdomEHA21AML

First-in-human study of teclistamab for relapsed/refractory Multiple Myeloma

/ Niels van de Donk
EHA21Myelomatose Play the Video
Back to top